|
甲状腺肿瘤CD15抗原表达及临床意义 |
| |
谷化平 尚培中 纪小龙 苏红 李春光
摘 要：目的 研究甲状腺癌组织中CD15抗原的表达情况及其临床意义。方法 应用微波-LSAB免疫组织化学法，检测50例甲状腺癌、45例甲状腺腺瘤、20例癌旁甲状腺组织和10例正常甲状腺组织中CD15抗原的表达。结果 在甲状腺癌中CD15表达阳性率为68.0%，显著高于甲状腺腺瘤(42.0%)和癌旁甲状腺组织(35.0%)(P＜0.05)，10例正常甲状腺组织中2例呈CD15弱阳性反应。CD15表达与甲状腺癌组织类型无关，在淋巴结转移病例和病理分期Ⅲ～Ⅳ期病例，CD15表达阳性率显著高于相应的无淋巴结转移病例和病理分期Ⅰ～Ⅱ期病例(P＜0.05)。CD15阳性的甲状腺癌复发及死亡率显著高于CD15阴性者(P＜0.05)。结论 CD15表达对甲状腺癌及恶性程度的判断、生物学行为预测和预后评估是一种很有意义的指标。
关键词：甲状腺肿瘤； 癌； 抗原，CD15； 免疫组织化学
Expression of CD15 antigen in thyroid neoplasma and its Clinical significance
GU Huaping SHANG Peizhong JI Xiaolong et al
（PLA 251st Hospital,Zhangjiakou 075000）
Abstract：Objective To study the expression of CD15 antigen in thyroid neoplasms and its clinical significance. Methods The expression of CD15 antigen in 50 thyroid cancers, 45 adenomas, 20 adjacent noncancerous portions and 10 normal thyroid tissues were investigated by microwave-LSAB immunohistochemical technique. Results The expression rate of CD15 in thyroid cancer was 68.0%, which was significantly higher than 35.0% in adjacent noncancerous portions and 42.0% in adenomas (P＜0.05). CD15 immunoreactivity was weakly positive in 2 of 10 normal tissues. No correlation was observed between expressions of CD15 and histological grading of thyroid cancer. The expressions of CD15 in cases with lymph node metastasis and of grade Ⅲ～Ⅳ were higher than that in cases without metastasis and of grade Ⅰ～Ⅱ (P＜0.05). The percentage of recurrence and death in CD15 positive cases with thyroid cancer was notably higher than that in negative cases with thyroid cancer (P＜0.05). Conclusion The expression of CD15 can be regarded as a parameter for evaluating the degree of malignancy, biological behavior and prognosis of thyroid cancer.
Key words：Thyroid neoplasms; Carcinoma; Antigens, CD15; Immunohistochemistry▲
CD15抗原(粒细胞相关抗原，或Lewis x)是Lewis血型抗原之一，属细胞粘附分子(CAMs)家族成员，为选择素所识别的比较确定的一个配基〔1，2〕。近年来研究表明，CD15表达与许多肿瘤的发生发展、侵袭转移及预后密切相关〔1-7〕。我们[1] [2] 下一页
上一个医学论文： 肾综合征出血热患者降钙基因相关肽的动态检测及意义
下一个医学论文： 男性青少年肥胖伴乳房发育症对性发育的影响
|
|
|
|
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文